<DOC>
	<DOCNO>NCT02332356</DOCNO>
	<brief_summary>This randomize , control study aim evaluate impact therapeutic intervention ( step ) patient clinical remission Magnetic Resonance Enterocolonography ( MREC ) active . In addition , evaluate impact therapeutic step patient archive clinical MREC remission . The primary endpoint rate clinical remission 104 week .</brief_summary>
	<brief_title>Therapeutic Optimization Study Based MR Enterocolonography Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Clinical diagnosis Crohn 's proven history disease clinical remission ( CDAI &lt; 150 ) Signed write consent form enroll study ( Need agreement deputy patient 20years old ) Contraindication infliximab , adalimumab , azathioprine Lactating woman Presence malignancy Within 3 month intestinal surgery Presence end stoma Planned surgery</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Crohn Disease</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Disease Attributes</keyword>
</DOC>